GeneBioTech Co. Ltd Net Assets
GeneBioTech Co. Ltd net assets. Based on the latest financial reports, GeneBioTech Co. Ltd (086060) has net assets worth ₩56.25 Billion KRW (≈ $38.12 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩80.28 Billion ≈ $54.40 Million USD) and total liabilities (₩24.02 Billion ≈ $16.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore GeneBioTech Co. Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩56.25 Billion |
| % of Total Assets | 70.08% |
| Annual Growth Rate | 7.2% |
| 5-Year Change | 25.15% |
| 10-Year Change | 40.94% |
| Growth Volatility | 9.92 |
Net Assets of GeneBioTech Co. Ltd (2009–2025)
Net assets of GeneBioTech Co. Ltd from 2009 to 2025. This chart illustrates how GeneBioTech Co. Ltd's net assets have evolved over time, based on quarterly financial data. See GeneBioTech Co. Ltd net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for GeneBioTech Co. Ltd (2009–2025)
The table below shows the annual net assets of GeneBioTech Co. Ltd from 2009 to 2025. For live market cap and overall valuation, see 086060 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩55.00 Billion ≈ $37.27 Million |
+7.89% |
| 2024-12-31 | ₩50.97 Billion ≈ $34.54 Million |
+5.52% |
| 2023-12-31 | ₩48.30 Billion ≈ $32.74 Million |
+5.64% |
| 2022-12-31 | ₩45.73 Billion ≈ $30.99 Million |
+4.05% |
| 2021-12-31 | ₩43.95 Billion ≈ $29.78 Million |
-2.44% |
| 2020-12-31 | ₩45.04 Billion ≈ $30.52 Million |
-4.02% |
| 2019-12-31 | ₩46.93 Billion ≈ $31.80 Million |
-2.16% |
| 2018-12-31 | ₩47.96 Billion ≈ $32.50 Million |
+18.46% |
| 2017-12-31 | ₩40.49 Billion ≈ $27.44 Million |
+3.76% |
| 2016-12-31 | ₩39.02 Billion ≈ $26.44 Million |
+35.32% |
| 2015-12-31 | ₩28.84 Billion ≈ $19.54 Million |
+23.13% |
| 2014-12-31 | ₩23.42 Billion ≈ $15.87 Million |
+1.39% |
| 2013-12-31 | ₩23.10 Billion ≈ $15.65 Million |
+8.58% |
| 2012-12-31 | ₩21.27 Billion ≈ $14.42 Million |
+9.21% |
| 2011-12-31 | ₩19.48 Billion ≈ $13.20 Million |
+6.00% |
| 2010-12-31 | ₩18.38 Billion ≈ $12.45 Million |
+1.64% |
| 2009-12-31 | ₩18.08 Billion ≈ $12.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GeneBioTech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3588898262000.0% over the analyzed period, indicating profitable operations and earnings retention.
GeneBioTech Co. Ltd Net Assets Breakdown (December 2025)
GeneBioTech Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩35.89 Billion | 65.26% |
| Other Components | ₩19.11 Billion | 34.74% |
| Total Equity | ₩55.00 Billion | 100.00% |
GeneBioTech Co. Ltd Competitors by Market Cap
The table below lists competitors of GeneBioTech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Luks Kadife Ticaret ve Sanayi AS
IS:LUKSK
|
$28.84 Million |
|
Greggs PLC
LSE:GRG
|
$28.85 Million |
|
Hilbert Group AB Series B
ST:HILB-B
|
$28.85 Million |
|
Nsys Co. Ltd.
KQ:333620
|
$28.85 Million |
|
Nova Wellness Group Bhd
KLSE:0201
|
$28.81 Million |
|
DGR Global Ltd
AU:DGR
|
$28.80 Million |
|
Latrobe Magnesium Ltd
AU:LMG
|
$28.78 Million |
|
Sapmer
PA:ALMER
|
$28.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneBioTech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 50,972,317,840 to 54,995,936,090, a change of 4,023,618,250 (7.9%).
- Net income of 3,788,812,150 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.79 Billion | +6.89% |
| Other Changes | ₩234.81 Million | +0.43% |
| Total Change | ₩- | 7.89% |
Book Value vs Market Value Analysis
This analysis compares GeneBioTech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.12x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4531.87 | ₩5080.00 | x |
| 2017-12-31 | ₩4702.18 | ₩5080.00 | x |
| 2018-12-31 | ₩5570.29 | ₩5080.00 | x |
| 2019-12-31 | ₩5450.16 | ₩5080.00 | x |
| 2020-12-31 | ₩5231.12 | ₩5080.00 | x |
| 2021-12-31 | ₩5103.62 | ₩5080.00 | x |
| 2022-12-31 | ₩5310.44 | ₩5080.00 | x |
| 2023-12-31 | ₩5609.93 | ₩5080.00 | x |
| 2024-12-31 | ₩5919.72 | ₩5080.00 | x |
| 2025-12-31 | ₩6387.01 | ₩5080.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneBioTech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.89%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.17%
- • Asset Turnover: 1.20x
- • Equity Multiplier: 1.38x
- Recent ROE (6.89%) is above the historical average (3.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 3.96% | 4.08% | 0.59x | 1.63x | ₩-1.09 Billion |
| 2010 | 5.68% | 5.67% | 0.64x | 1.58x | ₩-809.52 Million |
| 2011 | 2.72% | 1.89% | 0.63x | 2.30x | ₩-1.46 Billion |
| 2012 | 2.95% | 1.02% | 1.29x | 2.26x | ₩-1.43 Billion |
| 2013 | 0.88% | 0.37% | 1.14x | 2.09x | ₩-2.11 Billion |
| 2014 | 4.47% | 2.11% | 1.09x | 1.94x | ₩-1.35 Billion |
| 2015 | 5.94% | 3.28% | 1.06x | 1.71x | ₩-1.17 Billion |
| 2016 | 7.01% | 4.91% | 0.94x | 1.52x | ₩-1.17 Billion |
| 2017 | 5.16% | 3.76% | 0.93x | 1.47x | ₩-1.96 Billion |
| 2018 | 5.59% | 4.27% | 0.86x | 1.51x | ₩-2.11 Billion |
| 2019 | 1.80% | 1.45% | 0.86x | 1.45x | ₩-3.85 Billion |
| 2020 | -5.20% | -3.96% | 0.95x | 1.38x | ₩-6.85 Billion |
| 2021 | -1.10% | -0.77% | 1.04x | 1.37x | ₩-4.88 Billion |
| 2022 | 3.33% | 1.84% | 1.29x | 1.40x | ₩-3.05 Billion |
| 2023 | 5.36% | 3.26% | 1.20x | 1.37x | ₩-2.24 Billion |
| 2024 | 5.62% | 3.45% | 1.15x | 1.41x | ₩-2.23 Billion |
| 2025 | 6.89% | 4.17% | 1.20x | 1.38x | ₩-1.71 Billion |
Industry Comparison
This section compares GeneBioTech Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $101,034,626,727
- Average return on equity (ROE) among peers: 12.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneBioTech Co. Ltd (086060) | ₩56.25 Billion | 3.96% | 0.43x | $28.82 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $266.11 Billion | -4.10% | 0.95x | $2.49 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $2.55 Billion | 158.01% | 22.83x | $21.80 Million |
| NatureCell Co.Ltd (007390) | $13.75 Billion | 13.78% | 0.78x | $793.12 Million |
| Sam-A Pharm. Co. Ltd (009300) | $200.47 Billion | 10.66% | 0.15x | $56.13 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $259.82 Billion | 4.88% | 0.12x | $78.42 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $46.98 Million |
| Oscotec Inc (039200) | $21.78 Billion | -9.28% | 0.67x | $674.16 Million |
| EstechPharma Co. Ltd (041910) | $115.63 Billion | 3.31% | 0.05x | $42.90 Million |
| Komipharm International Co. Ltd (041960) | $60.02 Billion | -6.63% | 0.98x | $343.99 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $42.95 Billion | 6.15% | 0.28x | $25.96 Million |
About GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.